Hot Pursuit     22-Apr-24
Biocon jumps after receiving SAHPRA approval for Tacrolimus capsules
Biocon added 3.31% to Rs 270.45 after the company has received an approval from South African Health Products Regulatory Authority (SAHPRA) for their vertically integrated, complex drug product Tacrolimus capsule in South Africa.
Tacrolimus, a calcineurin inhibitor, is an immunosuppressant used in the treatment of organ transplant patients which reduces the body’s ability to reject a transplanted organ. It has been particularly effective in treating patients of renal transplant for more than two decades.

Biocon is an innovation led global biopharmaceuticals company, engaged in the production of therapies for chronic conditions like diabetes, cancer and autoimmune. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as Generic Formulations in the US, Europe & key emerging markets. It also has a pipeline of promising novel assets in immunotherapy under development.

The company had reported consolidated net profit of Rs 660 crore in Q3 FY24 as compared with net loss of Rs 41.8 crore posted in Q3 FY23. Revenue from operations jumped 34.43% year on year (YoY) to Rs 3,953.7 crore in the quarter ended 31 December 2023.

Previous News
  Stock Alert: Indegene, Wipro, Biocon, HUDCO
 ( Market Commentary - Stock Alert 13-May-24   08:28 )
  Board of Biocon recommends final dividend
 ( Corporate News - 16-May-24   17:54 )
  Biocon gets US FDA nod for fungal infection drug
 ( Hot Pursuit - 04-Jun-24   11:18 )
  Biocon arm gets USFDA nod for chronic heart failure drug
 ( Hot Pursuit - 02-Sep-24   08:59 )
  Biocon Biologics receives GMP certifications for its Indian and Malaysian manufacturing units
 ( Corporate News - 24-Jun-24   09:01 )
  Biocon's new monoclonal antibodies facility in India get manufacturing approval from EMA
 ( Hot Pursuit - 24-Jun-24   09:34 )
  Biocon inks pact with Medix to commercialize weight mgmt product
 ( Hot Pursuit - 13-May-24   08:05 )
  Board of Biocon appoints director
 ( Corporate News - 27-Jul-23   12:46 )
  USFDA classifies inspection of Biocon Biologic's Malaysian unit as 'OAI'
 ( Corporate News - 18-Oct-23   09:28 )
  Biocon's subsidiary receives UK’s MHRA approval for Aflibercept biosimilar
 ( Hot Pursuit - 13-Nov-23   17:05 )
  Biocon gains after arm inks distribution agreement with Sandoz
 ( Hot Pursuit - 26-Dec-23   10:40 )
Other Stories
  Sharda Cropchem Ltd Spikes 7.83%
  05-Nov-24   09:30
  Prestige Estates Projects Ltd Slides 1.06%
  05-Nov-24   09:30
  Sandur Manganese to acquire additional 20% stake in ASPL
  05-Nov-24   08:45
  SPARC drops as Q2 net loss widens to Rs 107 crore
  04-Nov-24   17:01
  Tube Investments ends lower after Q2 PAT drops over 18% YoY even as revenue rises
  04-Nov-24   15:48
  IRFC Q2 PAT rises 4% YoY to Rs 1,612 cr
  04-Nov-24   15:42
  Exide Inds Q2 PAT rises 4% YoY to Rs 298 crore
  04-Nov-24   15:17
  Poly Medicure Ltd leads losers in 'A' group
  04-Nov-24   15:00
  Hatsun Agro Product slips as Q2 PAT slides 17% YoY to Rs 64 cr
  04-Nov-24   14:51
  Prudent Corporate Advisory Services Ltd leads losers in 'B' group
  04-Nov-24   14:45
Back Top